Items where authors include "Twelves, C"

Article

Schramm, MWJ, Currie, S, Lee, MT et al. (9 more authors) (2023) Do animal models of brain tumors replicate human peritumoral edema? a systematic literature search. Journal of Neuro-Oncology, 161 (3). pp. 451-467. ISSN 0167-594X

Winter, M, Coleman, R, Kendall, J orcid.org/0000-0003-2884-4849 et al. (13 more authors) (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35. 100442. ISSN 2212-1374

Howell, SJ, Casbard, A, Carucci, M et al. (14 more authors) (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology, 23 (7). pp. 851-864. ISSN 1470-2045

Saini, KS and Twelves, C (2021) Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. British Journal of Cancer. ISSN 0007-0920

Twelves, C, Sabel, M, Checketts, D et al. (6 more authors) (2021) A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer, 124 (1). pp. 1379-1387. ISSN 0007-0920

O’Shaughnessy, J, Cortes, J, Twelves, C et al. (5 more authors) (2020) Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports, 10 (1). 11203. ISSN 2045-2322

Twelves, C, Cheeseman, S, Sopwith, W et al. (9 more authors) (2020) Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer, 20 (1). 53. ISSN 1471-2407

Cortes, J and Twelves, C (2020) Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis. Breast Journal, 26 (7). pp. 1347-1351. ISSN 1075-122X

de Bono, J, Lin, C-C, Chen, L-T et al. (20 more authors) (2020) Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. British Journal of Cancer, 122 (9). pp. 1324-1332. ISSN 0007-0920

Coleman, R, Brown, J, Rathbone, E et al. (9 more authors) (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 21. 89. ISSN 1745-6215

Jove, M, Spencer, J, Clench, M et al. (2 more authors) (2019) Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. Critical Reviews in Oncology/Hematology, 141. pp. 153-162. ISSN 1040-8428

Tripathy, D, Tolaney, SM, Seidman, AD et al. (9 more authors) (2019) ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncology, 15 (19). pp. 2211-2225. ISSN 1479-6694

Kirschbrown, WP, Kagedal, M, Wang, B et al. (15 more authors) (2019) Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology, 83 (6). pp. 1147-1158. ISSN 0344-5704

Twelves, C, Anthoney, A, Savulsky, CI et al. (9 more authors) (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120 (6). pp. 579-586. ISSN 0007-0920

Rugo, HS, Cortes, J, Awada, A et al. (12 more authors) (2018) Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 24 (14). pp. 3348-3357. ISSN 1078-0432

Perkins, EJ, Posada, M, Kellie Turner, P et al. (3 more authors) (2018) Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. European Journal of Drug Metabolism and Pharmacokinetics, 43 (3). pp. 355-367. ISSN 0378-7966

Blackwell, K, Gligorov, J, Jacobs, I et al. (1 more author) (2018) The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. Clinical Breast Cancer, 18 (2). pp. 95-113. ISSN 1526-8209

Başaran, GA, Twelves, C, Diéras, V et al. (2 more authors) (2018) Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 63. pp. 144-155. ISSN 0305-7372

Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (vol 165, pg 329, 2017). Breast Cancer Research and Treatment, 166 (1). pp. 327-328. ISSN 0167-6806

Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 165 (2). pp. 329-341. ISSN 0167-6806

Baker, K, Dunwoodie, E, Jones, RG et al. (8 more authors) (2017) Process Mining Routinely Collected Electronic Health Records to Define Real-Life Clinical Pathways during Chemotherapy. International Journal of Medical Informatics, 103. pp. 32-41. ISSN 1386-5056

Twelves, C, Cortés, J, Shaughnessy, JO et al. (16 more authors) (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial. European Journal of Cancer, 76. pp. 205-215. ISSN 0959-8049

Cortés, J, Rugo, HS, Twelves, C et al. (10 more authors) (2016) Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 5 (1). 1033. ISSN 2193-1801

Dorling, L, Kar, S, Michailidou, K et al. (12 more authors) (2016) The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity: A case-control study. PLoS ONE, 11 (7). ISSN 1932-6203

Twelves, C, Awada, A, Cortes, J et al. (6 more authors) (2016) Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer: Basic and Clinical Research, 10. pp. 77-84.

Hawsawi, Y, Humphries, MP orcid.org/0000-0003-1306-7012, Wright, A et al. (8 more authors) (2016) Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro. Oncotarget, 7 (22). pp. 32129-32143. ISSN 1949-2553

Twelves, C, Jove, M, Gombos, A et al. (1 more author) (2016) Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. Critical Reviews in Oncology/Hematology, 100. pp. 74-87. ISSN 1040-8428

Cortes, J, Hudgens, S, Twelves, C et al. (7 more authors) (2015) Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast cancer research and treatment, 154 (3). 509 - 520. ISSN 0167-6806

Kaufman, PA, Awada, A, Twelves, C et al. (7 more authors) (2015) Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 33 (6). pp. 594-601. ISSN 0732-183X

Chu, E, Haller, D, Cartwright, T et al. (7 more authors) (2014) Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. British Journal of Cancer, 110 (6). pp. 1438-1445. ISSN 0007-0920

Downing, A, Twelves, C, Forman, D et al. (2 more authors) (2014) Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast Journal, 20 (1). 29 - 36. ISSN 1075-122X

Hawsawi, Y, El-Gendy, R, Twelves, C et al. (2 more authors) (2013) Insulin-like growth factor - Oestradiol crosstalk and mammary gland tumourigenesis. BBA - Reviews on Cancer, 1836 (2). 345 - 353. ISSN 0304-419X

Kaufmann, PA, Cortes, J, Awada, A et al. (8 more authors) (2013) A Phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. Onkologie: international journal for cancer research and treatment, 36 (Suppl 7). p. 97. ISSN 0378-584X

Conference or Workshop Item

Baird, R, Oliveira, M, Ciruelos Gil, EM et al. (33 more authors) (2021) Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. In: 2020 San Antonio Breast Cancer Virtual Symposium, 08-11 Dec 2020, San Antonio, Texas, USA.

Winter, M, Kendall, J, Brown, S orcid.org/0000-0002-7975-7537 et al. (9 more authors) (2021) PS14-02: A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. In: 2020 San Antonio Breast Cancer Virtual Symposium, 08-11 Dec 2020, San Antonio, Texas, USA.

Franzoi, MA, Procter, M, Emond, O et al. (9 more authors) (2021) PS7-21: Timelines to initiate an adjuvant phase III trial across the globe: A sub-analysis of the APHINITY trial. In: 2020 San Antonio Breast Cancer Symposium, 08-11 Dec 2020, Online.

Anthoney, A, Samson, A orcid.org/0000-0002-3081-7850, West, E et al. (14 more authors) (2018) Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. In: 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, Il, USA.

Proceedings Paper

Leif, F, Pfänder, P, Murtuza Baker, S et al. (8 more authors) (2019) Nuclear receptor profiling predicts chemical disruptors as risk factors for developing breast cancer. In: Endocrine Abstracts (2019). Society for Endocrinology BES 2019, 11-13 Nov 2019, Brighton, UK. Society for Endicronology .

Samson, A orcid.org/0000-0002-3081-7850, West, E, Turnbull, S et al. (13 more authors) (2019) 1213P: Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. In: Abstract Book of the 44th ESMO Congress. European Society for Medical Oncology (ESMO) 2019 Congress, 27 Sep - 01 Oct 2019, Barcelona, Spain. Oxford University Press , v475-v532.

Jones, RH, Carucci, M, Casbard, AC et al. (10 more authors) (2019) Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

Twelves, C, Cheeseman, S, Thompson, M et al. (8 more authors) (2019) "Real world" characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC). In: Cancer Research. 2018 San Antonio Breast Cancer Symposium, 04-08 Dec 2018, San Antonio, Texas, USA. American Association for Cancer Research .

Cheeseman, S, Thompson, M, Riaz, M et al. (9 more authors) (2018) Characteristics and treatment patterns in patients with locally advanced and metastatic hormone receptor positive (HR+ ), human epidermal growth factor 2 negative (HER2-) breast cancer in clinical practice: retrospective analysis from Leeds Cancer Centre. In: Value in Health. ISPOR Europe 2018, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S51-S51.

Jove Casulleras, M, Spencer, J, Loadman, P et al. (7 more authors) (2018) Abstract 4926: Preclinical intratumoral pharmacokinetics (PK) of capecitabine (Cap) given +/- eribulin (Eri). In: Cancer Research. AACR Annual Meeting 2018, 14-18 Apr 2018, Chicago, IL, USA. American Association for Cancer Research .

Ferrari, L, Gerratana, L, Jove, M et al. (4 more authors) (2016) Clinical decision making in patients with metastatic breast cancer in the United Kingdom (UK) and Italy. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen, Denmark. Oxford University Press .

Ferrari, L, Gerratana, L, Jove, M et al. (16 more authors) (2016) Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy. In: Annals of Oncology. XVIII National Congress of Medical Oncology, 28-30 Oct 2016, Rome, Italy. Oxford University Press , iv63-iv63.

O'Shaughnessy, J, Rugo, H, Awada, A et al. (16 more authors) (2016) Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM). In: European Journal of Cancer. 10th European Breast Cancer Conference (EBCC-10), 09-11 Mar 2016, Amsterdam, Netherlands. Elsevier , S111-S112.

Hawsawi, YM, Jove, M, Humphries, M et al. (5 more authors) (2015) Role of Insulin like Growth Factor Binding Proteins and Tamoxifen Resistance in Breast Cancer Epithelial Cells. In: Journal of Pathology. Dublin Pathology 2015. 8th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 23-25 Jun 2015, Dublin, Ireland. Wiley , S19-S19.